SIC
ANIP icon

Samalin Investment Counsel’s ANI Pharmaceuticals ANIP Stock Holding History

Samalin Investment Counsel’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$651K Buy
7,865
+1
+0% +$80 0.2% 125
2026
Q1 		$605K Buy
+7,864
New +$614K 0.21% 137

Other funds holding ANIP

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
MMA
Mizuho Markets Americas New York $6.37B AUM 47.14% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
MCM
Marathon Capital Management Hunt Valley, Maryland $494M AUM 42.6% 1-Year Est. Return
RL
Ruffer LLP London, United Kingdom $2.83B AUM 30.34% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM

Samalin Investment Counsel's ANIP Position: Q2 2026 in Review

Samalin Investment Counsel increased its ANI Pharmaceuticals (ANIP) stake by 0.01% in Q2 2026, buying an estimated $80 and bringing the position to 7,865 shares worth $651K. The position accounts for 0.2% of the portfolio, ranked #125.

Samalin Investment Counsel first reported a position in ANIP in Q1 2026 and has held it in 2 quarters since. 75 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Samalin Investment Counsel held 7,865 shares of ANI Pharmaceuticals worth $651K as of Q2 2026.
  • Samalin Investment Counsel bought 1 ANI Pharmaceuticals share in Q2 2026, an estimated $80.
  • ANI Pharmaceuticals made up 0.2% of Samalin Investment Counsel's portfolio in Q2 2026, its #125 holding.
  • Samalin Investment Counsel first reported a position in ANI Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 75 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Samalin Investment Counsel's 13F filing for Q2 2026, filed 27 Jul 2026.